ArticleBMC cancer2026
Identification of endometrial cancer biomarkers using weighted gene coexpression network analysis and machine learning.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEndometrial carcinoma (UCEC) exhibits a rising incidence in China, imposing a substantial burden on both women and society. Identifying biomarkers for UCEC is critical for precise diagnosis and treatment.
methodsRNA-seq data for UCEC and normal endometrial tissues were sourced from the GEO and TCGA databases. The Limma package was used to analyze differentially expressed genes (DEGs) from GEO datasets, while weighted gene co-expression network analysis (WGCNA) was employed to identify gene modules associated with UCEC. Machine learning algorithms (GBM, KNN, LASSO, SVM, NNET, RF, DT, GLM) were subsequently applied for further gene screening. Key biomarkers were identified by analyzing overall survival (OS) and progression-free survival (PFS) using TCGA-UCEC data on the Xiantao Academic online analysis platform.Functional enrichment analysis, clinical significance assessment, COX regression analysis, prognostic nomogram construction, single-gene logistic regression analysis, potential mechanism exploration, and immune characterization were all conducted via the Xiantao Academic online analysis platform. Drug sensitivity profiling was performed using the CPADS database, followed by molecular docking validation. In vitro functional assays included the EdU assay for evaluating cell proliferation and the Transwell assay for assessing cell invasion.
resultsKaplan-Meier survival analysis showed that both overall survival (OS) and progression-free survival (PFS) were significantly shorter in the high-MAL-expression group than in the low-expression group, suggesting a close association between high MAL expression and poor prognosis. Further multivariate Cox regression analysis, which included clinical stage and tumor grade, revealed that the independent predictive value of MAL for OS was attenuated, indicating that its prognostic significance may be partially confounded by traditional clinicopathological factors. MAL may serve as a potential biomarker in UCEC patients, with its high expression promoting tumor progression, correlating negatively with prognosis, and modulating immune characteristics. In vitro experiments demonstrated that elevated MAL expression promoted the proliferation and invasion of ECC-1 cells, while MAL knockdown suppressed these phenotypes.
conclusionThis study found that high MAL expression is significantly correlated with poor prognosis in endometrial cancer patients, which is consistent with its functional role in promoting tumor cell proliferation and invasion. However, after adjusting for clinical factors such as stage and grade, the independent prognostic effect of MAL on overall survival was not prominent, suggesting that it may more likely reflect the extent of tumor progression and adverse clinical features, rather than serving as a sole determinant of prognosis. Therefore, MAL can be regarded as a molecular marker closely associated with disease progression and survival outcomes, and it holds potential for providing auxiliary value in risk stratification and personalized management when combined with clinical parameters.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.